alendronate has been researched along with Calcinosis in 19 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Calcinosis: Pathologic deposition of calcium salts in tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this study was to determine whether the osteoporosis treatment agent alendronate accelerates the rate of CAC." | 7.71 | Progression of coronary artery calcification in patients taking alendronate for osteoporosis. ( Adams, JS; Aziz, D; Emerick, AM; Gjertson, D; Goldin, JG; Greaser, LD; Hill, JA; Khorrami, S; Yoon, HC, 2002) |
| "A 6-year-old boy with improving juvenile dermatomyositis (JDM) developed severe and debilitating calcinosis, unresponsive to diltiazem and probenecid." | 5.33 | Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. ( Ambler, GR; Chaitow, J; McDonald, DW; Ouvrier, RA; Rogers, M, 2005) |
| " The objective of this study was to determine whether the osteoporosis treatment agent alendronate accelerates the rate of CAC." | 3.71 | Progression of coronary artery calcification in patients taking alendronate for osteoporosis. ( Adams, JS; Aziz, D; Emerick, AM; Gjertson, D; Goldin, JG; Greaser, LD; Hill, JA; Khorrami, S; Yoon, HC, 2002) |
| " The patient who had dystrophic calcinosis had a dramatic improvement with the introduction of alendronate." | 3.71 | New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. ( Horev, G; Mimouni, M; Mukamel, M, 2001) |
| "Alendronate may inhibit rat aorta calcification by up-regulating osteopontin and osteoprotegerin expression." | 1.38 | The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat. ( Jia, P; Li, Y; Liu, K; Wang, J; Wang, Z; Zhang, F, 2012) |
| "A 6-year-old boy with improving juvenile dermatomyositis (JDM) developed severe and debilitating calcinosis, unresponsive to diltiazem and probenecid." | 1.33 | Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. ( Ambler, GR; Chaitow, J; McDonald, DW; Ouvrier, RA; Rogers, M, 2005) |
| "Alendronate can inhibit the artery calcification in rats." | 1.33 | [The effect of alendronate on arterial calcification in rat model]. ( Hu, T; Jia, GL; Li, H; Lü, R; Tao, HR; Wang, HC; Wang, J; Zhang, RQ, 2006) |
| "Bone resorption was increased in patients with connective tissue disease and severe dystrophic calcification." | 1.32 | Increased bone resorption and failure to respond to antiresorptive therapy in progressive dystrophic calcification. ( Bresnihan, B; FitzGerald, O; Freaney, R; McKenna, M; Murphy, E, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahrens, BJ | 1 |
| Li, L | 1 |
| Ciminera, AK | 1 |
| Chea, J | 1 |
| Poku, E | 1 |
| Bading, JR | 1 |
| Weist, MR | 1 |
| Miller, MM | 1 |
| Colcher, DM | 1 |
| Shively, JE | 1 |
| Iseri, K | 1 |
| Watanabe, M | 1 |
| Yoshikawa, H | 1 |
| Mitsui, H | 1 |
| Endo, T | 1 |
| Yamamoto, Y | 1 |
| Iyoda, M | 1 |
| Ryu, K | 1 |
| Inaba, T | 1 |
| Shibata, T | 1 |
| Chopra, M | 1 |
| Tendolkar, MS | 1 |
| Vardhan, V | 1 |
| Oliveira, JR | 1 |
| Oliveira, MF | 1 |
| Saini, I | 1 |
| Kalaivani, M | 1 |
| Kabra, SK | 1 |
| Matsui, I | 1 |
| Hamano, T | 1 |
| Mikami, S | 1 |
| Fujii, N | 1 |
| Takabatake, Y | 1 |
| Nagasawa, Y | 1 |
| Kawada, N | 1 |
| Ito, T | 1 |
| Rakugi, H | 1 |
| Imai, E | 1 |
| Isaka, Y | 1 |
| O'Neill, WC | 1 |
| Toussaint, ND | 1 |
| Lau, KK | 1 |
| Strauss, BJ | 1 |
| Polkinghorne, KR | 1 |
| Kerr, PG | 1 |
| Sterbakova, G | 1 |
| Vyskocil, V | 1 |
| Linhartova, K | 1 |
| Jia, P | 1 |
| Li, Y | 1 |
| Wang, J | 2 |
| Zhang, F | 1 |
| Liu, K | 1 |
| Wang, Z | 1 |
| Hill, JA | 1 |
| Goldin, JG | 1 |
| Gjertson, D | 1 |
| Emerick, AM | 1 |
| Greaser, LD | 1 |
| Yoon, HC | 1 |
| Khorrami, S | 1 |
| Aziz, D | 1 |
| Adams, JS | 1 |
| Murphy, E | 1 |
| Freaney, R | 1 |
| Bresnihan, B | 1 |
| McKenna, M | 1 |
| FitzGerald, O | 1 |
| Hayami, T | 1 |
| Pickarski, M | 1 |
| Wesolowski, GA | 1 |
| McLane, J | 1 |
| Bone, A | 1 |
| Destefano, J | 1 |
| Rodan, GA | 1 |
| Duong, LT | 1 |
| Ambler, GR | 1 |
| Chaitow, J | 1 |
| Rogers, M | 1 |
| McDonald, DW | 1 |
| Ouvrier, RA | 1 |
| Li, H | 1 |
| Jia, GL | 1 |
| Wang, HC | 1 |
| Zhang, RQ | 1 |
| Tao, HR | 1 |
| Lü, R | 1 |
| Hu, T | 1 |
| Cohen, H | 1 |
| Solomon, V | 1 |
| Alferiev, IS | 1 |
| Breuer, E | 1 |
| Ornoy, A | 1 |
| Patlas, N | 1 |
| Eidelman, N | 1 |
| Hägele, G | 1 |
| Golomb, G | 1 |
| Mori, K | 1 |
| Shioi, A | 1 |
| Jono, S | 1 |
| Nishizawa, Y | 1 |
| Morii, H | 1 |
| Mukamel, M | 1 |
| Horev, G | 1 |
| Mimouni, M | 1 |
| Price, PA | 1 |
| Faus, SA | 1 |
| Williamson, MK | 1 |
2 trials available for alendronate and Calcinosis
| Article | Year |
|---|---|
Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial.
Topics: Aged; Alendronate; Arteriosclerosis; Biomarkers; Blood Vessels; Bone and Bones; Bone Density; Bone R | 2019 |
Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial.
Topics: Aged; Alendronate; Aorta; Calcinosis; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Middle | 2010 |
17 other studies available for alendronate and Calcinosis
| Article | Year |
|---|---|
Diagnostic PET Imaging of Mammary Microcalcifications Using
Topics: Alendronate; Animals; Calcinosis; Cell Line, Tumor; Copper Radioisotopes; Disease Models, Animal; Fe | 2017 |
Case series of Pulmonary Alveolar Microlithiasis from India.
Topics: Adult; Alendronate; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Calcinosis; Cough; Dyspnea; | 2019 |
Primary brain calcification in patients undergoing treatment with the biphosphanate alendronate.
Topics: Adult; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Brain; Brain Diseases; Calc | 2016 |
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
Topics: Age of Onset; Alendronate; Calcinosis; Child; Child, Preschool; Delayed Diagnosis; Dermatomyositis; | 2016 |
Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failure.
Topics: Adenine; Alendronate; alpha-Fetoproteins; Animals; Calcinosis; Chemical Precipitation; Liver; Male; | 2009 |
Mineral complexes and vascular calcification.
Topics: Adenine; Alendronate; alpha-Fetoproteins; Animals; Biomarkers; Calcinosis; Calcium; Chemical Precipi | 2009 |
Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.
Topics: Aged; Alendronate; Aortic Valve Stenosis; Bone Density Conservation Agents; Calcinosis; Comorbidity; | 2010 |
The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat.
Topics: Alendronate; Animals; Aorta; Calcinosis; Calcium; Gene Expression Regulation; Male; Osteopontin; Ost | 2012 |
Progression of coronary artery calcification in patients taking alendronate for osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone and Bones; Calcinosis; Cal | 2002 |
Increased bone resorption and failure to respond to antiresorptive therapy in progressive dystrophic calcification.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcino | 2003 |
The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model.
Topics: Acid Phosphatase; Alendronate; Animals; Anterior Cruciate Ligament; Bone Remodeling; Calcinosis; Car | 2004 |
Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.
Topics: Alendronate; Calcinosis; Child; Dermatomyositis; Dose-Response Relationship, Drug; Drug Administrati | 2005 |
[The effect of alendronate on arterial calcification in rat model].
Topics: Alendronate; Animals; Aortic Diseases; Bone Density Conservation Agents; Calcinosis; Cell Proliferat | 2006 |
Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Betaine; Bone and Bones; Bone Resorption; Calcinosis | 1998 |
Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification.
Topics: Alendronate; Animals; Blotting, Northern; Calcinosis; Calcium; Calcium-Binding Proteins; Cattle; Cel | 1998 |
New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment.
Topics: Adolescent; Alendronate; Calcinosis; Dermatomyositis; Humans; Interleukin-1; Macrophages; Male; Trea | 2001 |
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diph | 2001 |